Equity markets have performed well in 2024, but their showing pales next to that of Viking Therapeutics (NASDAQ: VKTX), a mid ...

In trading on Tuesday, shares of Viking Therapeutics Inc (Symbol: VKTX) crossed below their 200 day moving average of $61.13, changing hands as low as $58.39 per share. Viking Therapeutics Inc ...

Below is Validea's guru fundamental report for VIKING THERAPEUTICS INC (VKTX). Of the 22 guru strategies we follow, VKTX rates highest using our Value Investor model based on the published ...

On Tuesday, Viking Therapeutics Inc (VKTX) stock saw a decline, ending the day at $60.6 which represents a decrease of $-2.37 or -3.76% from the prior close of $62.97. The stock opened at $62.46 and ...

Oppenheimer analyst Jay Olson maintained a Buy rating on Viking Therapeutics (VKTX – Research Report) today and set a price target of $164.00. The company’s shares closed yesterday at $55.06.

NEW YORK CITY, NY / ACCESSWIRE / November 16, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Viking Therapeutics, Inc. ("Viking" or the "Company") (NASDAQ:VKTX). Such investors ...

Right now, Viking does not have any treatments that are formally approved by the FDA. Nevertheless, the company's lead obesity candidate, VK2735, has garnered a lot of attention and is widely ...

NEW YORK, NY / ACCESSWIRE / November 14, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Viking Therapeutics, Inc. ("Viking Therapeutics, Inc.") (NASDAQ:VKTX) ...

Gainers: EKSO +22%. NDRM +13%. AEMD +9%. ALXN +8%. CRVS +7%.Losers: ATNM -17%. VKTX -11%. APTO -10%. ALDX -10%. RGLS -9%.Now read: Alexion: Suspicions Of Improper ...

Eli Lilly (NYSE: LLY) sells a broad range of pharmaceuticals treating various diseases, but one portfolio in particular has ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The stocks of companies that make or are developing the new class of weight-loss and diabetes-management drugs were sharply lower Friday, after President-elect Donald Trump named Robert F. Kennedy Jr.